<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03169803</url>
  </required_header>
  <id_info>
    <org_study_id>700022-01</org_study_id>
    <nct_id>NCT03169803</nct_id>
  </id_info>
  <brief_title>Cardiac Output Autonomic Stimulation Therapy for Acute Heart Failure (COAST-AHF)</brief_title>
  <official_title>Cardiac Output Autonomic Stimulation Therapy for Acute Heart Failure (COAST-AHF) - System Design Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NeuroTronik Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NeuroTronik Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A feasibility study to investigate the safety and performance of the NeuroTronik Cardiac
      Autonomic Nerve Stimulation (CANS) Therapy System
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A single-arm, safety study intended to assess safety and system performance, and the
      feasibility to improve hemodynamics in patients with acute heart failure syndrome using
      transvenous, cardiac autonomic nerve stimulation (CANS) therapy. In addition, the effects of
      NeuroTronik CANS Therapy™ on the congestion of patients will be studied. The study proposes
      that the NeuroTronik CANS Therapy™ System be deployed during the acute heart failure syndrome
      hospital admission, along with existing standard treatment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 19, 2017</start_date>
  <completion_date type="Anticipated">June 19, 2018</completion_date>
  <primary_completion_date type="Anticipated">May 19, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Device Feasibility</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Arterial blood pressure</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Heart Rate</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiac output</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary capillary wedge pressure</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Heart Failure Acute</condition>
  <arm_group>
    <arm_group_label>Single arm, NeuroTronik CANS Therapy System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>NeuroTronik CANS Therapy™ System</intervention_name>
    <description>The NeuroTronik CANS Therapy™ System is a percutaneous, catheter-based, bedside electrical stimulation system. The System consists of the single-use, disposable NeuroCatheter™ and NeuroCatheter™ Placement Kit, along with the reusable, bedside NeuroModulator™ Development System, and the NeuroTronik CANS Therapy™ Cable.</description>
    <arm_group_label>Single arm, NeuroTronik CANS Therapy System</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Left Ventricular Ejection fraction &lt; 40%, measured in the last year

          2. At least two of the following:

               -  Pulmonary Capillary Wedge Pressure &gt; 18 mmHg

               -  Pulmonary congestion on Chest X-ray

               -  Jugular vein distension

               -  Pulmonary rales

               -  Edema

               -  Dyspnea at rest

               -  Two (2) emergency room visits or hospital admissions in the past three (3)
                  months, or three (3) emergency room visits or admissions in the past six (6)
                  months requiring intravenous diuretics, ultrafiltration or in-hospital inotropic
                  therapy.

          3. With or without evidence of low perfusion

        Exclusion Criteria:

          1. Systolic Blood Pressure &lt; 90 mmHg or &gt; 160 mmHg

          2. Catecholamine or inotropic therapy within the previous 48 hours

          3. Levosimendan within the previous 72 hours

          4. Chronic outpatient catecholamine or inotropic therapy

          5. Presence of implanted pacemaker, implantable cardioverter defibrillator or cardiac
             resynchronization therapy device

          6. Presence of or prior vagal nerve stimulator

          7. Coronary artery bypass graft surgery, percutaneous coronary intervention, acute
             myocardial infarction, or valve replacement within prior 1 month

          8. Second or third degree heart block

          9. History of atrial or ventricular arrhythmias

         10. History of mitral or aortic valve stenosis or regurgitation

         11. Hypertrophic obstructive or infiltrative cardiomyopathy

         12. Prior vagotomy

         13. Prior heart transplant

         14. Narrow angle glaucoma

         15. Renal failure - either on dialysis or serum creatinine &gt; 2.0 mg/dl

         16. Hepatic failure - bilirubin, serum glutamic oxaloacetic transaminase, or serum
             glutamic pyruvic transaminase &gt; four times upper limit of normal

         17. Life expectancy &lt; 12 months per physician judgment

         18. Women who are pregnant

         19. Allergy to fentanyl, midazolam, propofol, eggs, egg products, soybeans, or soy
             products

         20. Subjects unwilling or unable to provide consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Temístocles Díaz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Punta Pacífica, Panama City, Panama</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Temístocles Díaz, MD</last_name>
    <phone>+507.204.8354</phone>
    <email>hemcicompany@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elsa I Abruzzo</last_name>
    <phone>+1.513.236.0857</phone>
    <email>elsa.abruzzo@neurotronikinc.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Punta Pacífica</name>
      <address>
        <city>Panama City</city>
        <country>Panama</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Temístocles Díaz, MD</last_name>
      <phone>+507.204.8354</phone>
      <email>hemcicompany@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Elsa Abruzzo</last_name>
      <phone>+1.513.236.0857</phone>
      <email>elsa.abruzzo@neurotronikinc.com</email>
    </contact_backup>
    <investigator>
      <last_name>Temístocles Díaz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Panama</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 25, 2017</study_first_submitted>
  <study_first_submitted_qc>May 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 30, 2017</study_first_posted>
  <last_update_submitted>January 25, 2018</last_update_submitted>
  <last_update_submitted_qc>January 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Electrical Stimulation Therapy</keyword>
  <keyword>Electrodes</keyword>
  <keyword>Parasympathetic Nervous System</keyword>
  <keyword>Sympathetic Fibers</keyword>
  <keyword>Post Ganglionic</keyword>
  <keyword>Congestive Heart Failure</keyword>
  <keyword>Heart Failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

